Real World Effectiveness and Tolerability of Novel Monoclonal Antibodies and Rituximab for NMOSD
Year: 2025
Type: article
Study design: Observational Study
Abstract: In this multicenter retrospective cohort study of 135 people with aquaporin-4 IgG+ neuromyelitis optica spectrum disorder (NMOSD), some of whom were exposed to multiple therapies, we evaluated the effectiveness and tolerability of rituximab (n = 111) and novel monoclonal antibodies (nMAbs): eculizumab (n = 9), inebilizumab (n = 23), and satralizumab (n = 14). Over a median follow-up of 3.92 years, 21/111 rituximab-treated patients relapsed. In contrast, relapse occurred in only 1/23 inebilizumab-treated patients (median follow-up 1.27 years), with no relapses observed in those receiving eculizumab or satralizumab. Twelve-month relapse-free probabilities were 92% (rituximab), 94% (inebilizumab), and 100% (eculizumab and satralizumab). Among those with available MRI data, 10/73 rituximab and 1/14 inebilizumab developed new lesions. There were no serious adverse events. These findings support nMAbs as effective and well-tolerated first-line therapies for NMOSD.
DOI: 10.1002/acn3.70160
Institutions: Cleveland Clinic, Lou Ruvo Brain Institute
Language: English
Subfield: Pathology and Forensic Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $4,100
Funders: Amgen, Bristol-Myers Squibb, Sanofi, Biogen, Patient-Centered Outcomes Research Institute, Alexion Pharmaceuticals, TG Therapeutics, Race to Erase MS, Horizon Therapeutics, Multiple Sclerosis Society, National Institutes of Health, Agency for Healthcare Research and Quality, Genentech, EMD Serono, National Institute of Neurological Disorders and Stroke
OpenAlex ID: W4413434807